Consortia
Collaborative medical research starts here
Secure and efficient consortia with Owkin
Data is never shared between partners, only the encrypted model weights travel between the data centers.
Owkin contributes its world leading AI and medical expertise in consortia to explore critical medical research questions.
Building the world’s largest spatial multiomics dataset in oncology
MOSAIC is a landmark research project to create a multimodal dataset with spatial transcriptomes from 7,000 patients in 7 cancer types. This is the largest spatial omics atlas to date.
The MOSAIC dataset will be 100x larger than existing efforts and will use cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, enabling AI to unlock potential for new breakthrough treatments.
Accelerating precision medicine through AI-enabled digital pathology
A landmark government-endorsed program to structure and scale the digital pathology ecosystem in France to augment and improve the diagnosis of cancer. The consortium brings together 6 partners from the public and private sectors: Owkin, Gustave Roussy, Tribun Health, Unicancer, Centre Léon Bérard and Cypath.
PortrAIt will enable pathology labs and research hospitals to work with technology pioneers to develop and deploy AI tools for digital pathology.
Active consortia
Setting up the first European ethical and regulatory compliant community-based platform bringing together an unprecedented amount of quality-controlled annotated pathology images and AI algorithms.
Generating molecular and cellular profiling data of the tumor and its microenvironment. Owkin is supporting genomic data analysis and prediction of treatment response using multimodal models.
Creating a sarcoma immune atlas exploring the sarcome environment. Owkin is developing an AI model to allow deployment of immunotherapy.
Completed consortia
Leverage federated learning to train machine learning models on histology slides and dermoscopy images to predict treatment response in breast cancer and melanoma patients.
Connect 10 pharma partners leveraging the world’s largest collection of small molecules with known biochemical or cellular activities for federated drug discovery.